Nuevolution publishes prospectus in connection with the listing on Nasdaq Stockholm

Stockholm, 20 June 2018, Nuevolution AB (publ) (Nuevolution” or the Company”) announced that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s main market. The prospectus that has been prepared in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority today on 20 June 2018 and is now available on Nuevolution’s website, 

The first day of trading on Nasdaq Stockholm occurs on 25 June 2018. Last day of trading on Nasdaq First North Premier is 21 June 2018. The ticker for the Company’s shares, NUE, will remain unchanged. The ISIN code for the Company’s shares, SE0007730650, will also remain unchanged. Shareholders in the Company do not need to take any action in connection with the list change.

For further information, please contact:

Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987       

Henrik D. Simonsen, CFO  
Phone: +
45 3913 0947       

The information was sent for publication, through the agency of the contact persons set out above, on 17.00 CET on 20 June 2018.

About Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links